AstraZeneca PLC (LON:AZN) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of AstraZeneca PLC (LON:AZN) have been given an average recommendation of “Moderate Buy” by the six brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is £153.33.

AZN has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating and set a £115 target price on shares of AstraZeneca in a report on Thursday, May 21st. Citigroup raised their price objective on AstraZeneca from £170 to £180 and gave the stock a “buy” rating in a research note on Friday, April 10th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a £180 price objective on shares of AstraZeneca in a research note on Wednesday, May 13th.

AstraZeneca Stock Down 0.7%

Shares of AZN stock opened at £137.12 on Monday. AstraZeneca has a 12 month low of £101.03 and a 12 month high of £157.32. The stock has a market cap of £212.65 billion, a P/E ratio of 20.65, a P/E/G ratio of 0.86 and a beta of 0.22. The company has a current ratio of 0.91, a quick ratio of 0.59 and a debt-to-equity ratio of 71.66. The company has a 50 day simple moving average of £142.43 and a two-hundred day simple moving average of £141.42.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.